Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system.
It is a $10.0M healthcare company.
- Website
- autonomix.com
- Location
- The Woodlands, TX
- Employees
- 11
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Valuation, Growth, Profitability, Quality and Moat lag behind.
Valuation30
- P/E vs own historyn/a · 10/25
- FCF yield-132.3% · 0/25
- P/Sn/a · 10/25
- EV/EBITDAn/a · 10/25
Growth0
- Revenue CAGRn/a · 0/25
- Net income CAGRn/a · 0/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growthn/a · 0/25
Profitability0
- ROICn/a · 0/25
- ROE-267.7% · 0/25
- Net marginn/a · 0/25
- Operating marginn/a · 0/25
Health53
- Altman Z-24.77 · 3/25
- Current ratio4.85 · 25/25
- Interest coverageno interest expense · 25/25
- Net cash / debtn/a · 0/25
Quality0
- Piotroski F1/9 · 0/25
- Beneish Mn/a · 0/25
- FCF conversionn/a · 0/25
- Margin stabilityn/a · 0/25
Moat0
- ROIC >12% yearsn/a · 0/25
- Median gross marginn/a · 0/25
- FCF-positive years0/3 yrs · 0/25
- Worst-year net marginn/a · 0/25
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
No standout strengths in the available data.
Watch-outs
- Negative free cash flow (-$13.2M)
- Altman Z-Score -24.77 — elevated financial-distress risk
- Loss-making in 5 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year agono data
- Profitable — makes more than it spends-$16.1M TTM
- Profit growing — earnings are higher than last year-46.5% YoY
- Generates cash — cash left after running and investing-$13.2M TTM
- Debt under control — could handle its obligationscurrent ratio 4.85
- Established company — not a micro-cap — lower blow-up risk$10.0M market cap
- Not printing shares — share count not ballooning — you keep your slice+362.4% shares over ~5y
- Proven track record — years of profitability behind it0/5 profitable years
- Financially stable — balance sheet not near distressAltman Z -24.8 — distress
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsno data
Peer comparisonAutonomix Medical, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| AMIX this company | $10M | — | — | — | Mixed |
| LLY Eli Lilly & Co. | $1.1T | 43.8 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $614.5B | 38.8 | +8.1% | 21.5% | Solid |
| ABBV Abbvie Inc. | $505.3B | 79.4 | +10.4% | 9.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $359.9B | 23.4 | +6.5% | 3.1% | Mixed |
| MRK Merck & Co., Inc. | $358.4B | 116.6 | +4.6% | 4.8% | Strong |
| NVS Novartis AG | $282.1B | 21.2 | +9.6% | 24.7% | Solid |
Head-to-head: AMIX vs LLY · AMIX vs JNJ · AMIX vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2022–FY2026. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/AMIX
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of AMIX on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $2.87 · market cap $10.0M.